Latest pulmonary atresia Stories
ATLANTA, April 9, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 first quarter financial results will be released on Tuesday, April 30, 2013. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief...
ATLANTA, Jan. 31, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2012 fourth quarter and year end financial results will be released on Thursday, February 14, 2013. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson,...
More than 152 Zoloft Lawsuits Pending in U.S District Court, Eastern District of Pennsylvania, Allege Zoloft Caused Birth Defects when Ingested by Pregnant Women. Melville, NY (PRWEB) October 01, 2012 The Zoloft birth defect lawyers at Alonso Krangle LLP, a leading national law firm focused on fighting for the rights of serious personal injury victims, report that the federal litigation recently established for Zoloft birth defect lawsuits is moving forward, with the litigation’s next...
ATLANTA, June 14, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has entered into a settlement agreement with CardioFocus, Inc. ending the outstanding patent dispute between CryoLife's wholly owned subsidiary, Cardiogenesis Corporation (acquired by CryoLife in May 2011), and CardioFocus that was pending in the United States District Court of Massachusetts. Under the terms of the...
ATLANTA, Oct. 13, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that ValveXchange, Inc., a company in which CryoLife owns a minority interest, has completed the first three human implants with its novel Vitality(TM) two-part heart valve system. The surgeries were performed in Asuncion, Paraguay and took place on Sept. 26 and 27, 2011. Three men aged 49, 62 and 72 received the...
ATLANTA, July 7, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today a $3.5 million equity investment in ValveXchange® Inc. ValveXchange is a private medical device company that was spun-off out of Cleveland Clinic to develop a lifetime heart valve replacement technology platform featuring exchangeable bioprosthetic leaflets. Under the agreement, CryoLife will receive an...
St. Joseph's Children's Hospital is among a small number of facilities in the country to offer the less-invasive procedure for valve replacement. TAMPA, Fla., June 9, 2011 /PRNewswire-USNewswire/ -- When cardiologists at St. Joseph's Children's Hospital told 21-year-old Adam Romano that he needed to have his pulmonary valve replaced, the diagnosis was not a surprise. Born with the congenital heart defect Tetralogy of Fallot, Adam underwent open-heart surgery when he was 2 years old and his...
ATLANTA, Oct. 12 /PRNewswire/ -- More than 100 cardiovascular surgeons and cardiologists from 25 countries are scheduled to attend the third annual global Ross Summit, a two-day surgical congress focused on the Ross Procedure. Filled with a number of point-counterpoint discussions, the forum will feature the presentation of much new data about the Ross Procedure and interactive discussions among many of the world's elite cardiovascular surgeons and cardiologists regarding survival, quality...
ATLANTA, Aug. 9 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular...
ATLANTA, June 8 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from the valve...
